Library Item - Page 26 of 792 Posts on Medivizor

Evaluating the predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence.

Posted by Medivizor on Jun 26, 2022 in Urinary incontinence | 0 comments

In a nutshell This study evaluated the factors that could predict the cure and overactive bladder (OAB) syndrome after a mid-urethral sling (MUS) procedure in women with stress urinary incontinence (SUI). The study found age and overactivity of the detrusor (bladder) before surgery were independent predictors of persisting/recurrent SUI. OAB before...

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

Evaluating the role of vitamin D supplementation in patients with breast cancer receiving doxorubicin chemotherapy.

Posted by Medivizor on Jun 26, 2022 in Breast cancer | 0 comments

In a nutshell The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers. Some background The main treatment for early...

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Posted by Medivizor on Jun 14, 2022 in Prostate cancer | 0 comments

In a nutshell The review investigated the effects of neoadjuvant chemo-hormonal therapy (NCHT; chemotherapy and hormonal therapy before surgery) in patients with prostate cancer (PCa). The results showed that compared to patients who received prostate surgery alone, NCHT before prostate surgery improved the oncological outcomes of these...

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Posted by Medivizor on Jun 5, 2022 in Prostate cancer | 0 comments

In a nutshell This review compared the outcomes of 2 techniques for robotic-assisted radical prostatectomy (RARP; complete removal of the prostate gland using robotic arms): Retzius-sparing (RS)-RARP and conventional (C)-RARP in patients with localized prostate cancer (PCa). The analysis showed that RS-RARP was associated with improved urinary...

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Posted by Medivizor on Jun 5, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

$Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma$

Posted by Medivizor on Jun 1, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of brentuximab-vedotin (Bv; Adcetris) combined with bendamustine (Treanda: B) as salvage treatment in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). This study concluded that this treatment is safe and effective in these patients....

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

Posted by Medivizor on Jun 1, 2022 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the safety and effectiveness of an immunomodulatory IDO/PD-L1 targeting peptide vaccine (IO102/IO103) combined with nivolumab (Opdivo) in patients with metastatic melanoma (MM). The study concluded that the IO102/IO103 vaccine combined with nivolumab is safe and effective in these...

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

Posted by Medivizor on Jun 1, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with primary central nervous system lymphoma (PCNSL) on high-dose methotrexate (HD-MTX; Otrexup)-based chemotherapy followed by non-myeloablative consolidation therapy. The study showed that HD-MTX-based chemotherapy with non-myeloablative consolidation therapy is an alternative and...

Does vitamin D supplementation affect ovarian reserve markers in women with infertility associated with diminished ovarian reserve?

Posted by Medivizor on Jun 1, 2022 in Infertility | 0 comments

In a nutshell This study evaluated the effects of vitamin D supplementation on ovarian reserve markers in women with infertility due to reduced ovarian reserves and vitamin D deficiency. The study showed possible beneficial effects on ovarian reserve markers with vitamin D supplementation in these women. Some background Ovarian reserve refers to the...

Can disease flare be predicted following remission and treatment withdrawal in patients with early rheumatoid arthritis?

Posted by Medivizor on Jun 1, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study identified predictors of disease flare in patients with early, active rheumatoid arthritis (RA) that had stopped methotrexate (MTX; Otrexup) and/or abatacept (Orencia) treatment after clinical remission was achieved at 12 months. The data showed that patient function (HAQ-DI) and bone erosion based on magnetic resonance...

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Posted by Medivizor on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival...

Library Item Posts on Medivizor

Evaluating the predictors of cure and overactive bladder syndrome after a mid-urethral sling procedure in women with stress urinary incontinence.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the role of vitamin D supplementation in patients with breast cancer receiving doxorubicin chemotherapy.

Reviewing chemotherapy and hormonal therapy before prostate surgery in patients with prostate cancer

Comparing Retzius-sparing and conventional robot-assisted radical prostatectomy for men with localized prostate cancer

Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.

Evaluating brentuximab-vedotin with bendamustine combination treatment before transplantation in patients with relapsed/refractory Hodgkin lymphoma

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

How effective is non-myeloablative chemotherapy after high-dose methotrexate-based treatment in patients with primary central nervous system lymphoma?

Does vitamin D supplementation affect ovarian reserve markers in women with infertility associated with diminished ovarian reserve?

Can disease flare be predicted following remission and treatment withdrawal in patients with early rheumatoid arthritis?

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Categories

Recent Posts

Archives

Library Item Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email